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Abstract B lymphocyte stimulator (BLyS, also indicated as
BAFF (B-cell activating factor) and CD257), and A Prolif-
eration Inducing Ligand (APRIL, CD256) are two members
of the TNF superfamily with a central role in B cell survival.
Antibodies against these factors have potential therapeutic
relevance in autoimmune inflammatory disorders with a
proven pathogenic contribution of B cells, such as multiple
sclerosis (MS). In the current study we performed a multi-
parameter efficacy comparison of monoclonal antibodies
against human anti-BLyS and anti-APRIL in a common
marmoset (Callithrix jacchus) model of experimental auto-
immune encephalomyelitis (EAE). A MS-like disease was
induced by immunization with recombinant human myelin/
oligodendrocyte glycoprotein (rhMOG) in complete Freund’s
adjuvant. The results show that the anti-BLyS and anti-APRIL
antibody cause significant depletion of circulating CD20+ B
cells, but a small subset of CD20+CD40high B cells was
not depleted. Induction of CD20+ B cell depletion from
lymph nodes was only observed in the anti-BLyS treated
monkeys. Both antibodies had a significant inhibitory ef-
fect on disease development, but all monkeys developed
clinically evident EAE. Anti-BLyS treated monkeys were
sacrificed with the same clinical signs as saline-treated
monkeys, but nevertheless displayed significantly reduced
spinal cord demyelination. This effect was not observed in
the anti-APRIL treated monkeys. The two antibodies had
a different effect on T cell subset activation and the
profiles of ex vivo released cytokines. In conclusion, treat-
ment with anti-BLyS and anti-APRIL delays the develop-
ment of neurological disease in a relevant preclinical
model of MS. The two mAbs achieve this effect via
different mechanisms.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the human central nervous system (CNS). The
disease is pathologically characterized by the presence of
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demyelinated lesions within the white as well as grey matter,
which contain a variable degree of inflammation and dam-
age to axons and neurons (Lassmann et al. 2007). Although
demyelinated lesions are likely formed by the synergy of
cellular and humoral immune mechanisms, most immuno-
therapies developed for MS target T cells (Lopez-Diego and
Weiner 2008). The results of two recent clinical trials seem
to have caused a paradigm shift in therapy development.
Unexpectedly, treatment of relapsing/remitting MS
(RRMS) patients using an antibody against human
anti-IL12p40 aiming at the simultaneous inhibition of
Th1 and Th17 T cell responses as demonstrated in
psoriasis (Laws and Warren 2011), showed no detect-
able clinical benefit in RRMS (Segal et al. 2008). On
the other hand, treatment of a similar group of patients
with monoclonal antibodies against human CD20, caus-
ing profound and long lasting depletion of B cells,
caused rapid and sustained suppression of neurological
symptoms (Barun and Bar-Or 2012).
Total CD20+ B cell ablation is a highly effective manner
to induce robust and long-lasting disease suppression in a
variety of autoimmune disorders, including rheumatoid ar-
thritis (RA), systemic lupus erythematosus (SLE) (Pers et al.
2008) and MS (Barun and Bar-Or 2012). However, the
treatment spares plasma cells it causes impairment of the
immune defence against new and latent infections. Occa-
sional reactivation of hepatitis B and C, and polyoma JC
virus can give rise to serious clinical complications (Carson
et al. 2009). This situation warrants the question whether
profound systemic B cell depletion is indeed needed for the
therapeutic effect or whether alternative B cell targeting
treatments may be equally beneficial.
The primary aim of this study was to test the efficacy of
two monoclonal antibodies, one for B Lymphocyte Stimu-
lator (BLyS), also known as B-cell Activating Factor
(BAFF, CD257) of the TNF family, and a second for A
Proliferation-Inducing Ligand (APRIL, CD256). Both cyto-
kines have an important role in the differentiation of B cells
(Daridon et al. 2008). A secondary aim of the study was to
obtain mechanistic information on the two antibodies by
examining changes of autoimmune reactions. The efficacy
of the two antibodies was tested in an experimental autoim-
mune encephalomyelitis (EAE) model in common marmo-
sets (Callithrix jacchus), induced by immunization with
recombinant human myelin/oligodendrocyte glycoprotein
(rhMOG) formulated in complete Freund’s adjuvant (CFA)
(Brok et al. 2000; Kap et al. 2008). This rhMOG/CFA EAE
model has been well established as a valid preclinical model
of MS for translational research into immunopathogenic
mechanisms and the preclinical evaluation of novel immu-
notherapies (’t Hart et al. 2011).
In a recent set of experiments we used HuMab 7D8, a
novel fully human IgG monoclonal antibody (mAb) that
binds the same epitope on human CD20 as ofatumumab to
examine the pathogenic contribution of B cells to this model
(Teeling et al. 2004; Kap et al. 2010). We reported that the
profound clinical effect antibody was caused by suppression
of cellular and humoral autoimmune mechanisms that lead
to lesion formation and neurological deficit (Kap et al. 2010;
Kap et al. 2011).
In the here reported study we used essentially the same
design for the efficacy testing of the anti-BLyS and anti-
APRIL antibodies. Both antibodies induced depletion of
CD20+ B-cells, which was reflected by suppressed autoan-
tibody production and modulation of T cell proliferation and
cytokine production. Both antibodies induced a significant
delay of the disease onset. The clinical effect of the anti-
BLyS antibody was stronger than of the anti-APRIL anti-
body. Treatment with the anti-BLyS antibody also lowered
demyelination of the spinal cord, whereas this was not
observed in monkeys treated with the anti-APRIL antibody.
Materials and methods
Animals
Eighteen adult male common marmosets (Callithrix jacchus)
were purchased from the outbred colony maintained at the
Biomedical Primate Research Centre (Rijswijk, The Nether-
lands). Individual data of all monkeys used in this study are
listed in Table 1. Before inclusion in the study the animals
were subjected to a complete physical, haematological and
biochemical examination. Only monkeys that were declared
healthy by the institute’s veterinarians were used. During the
study they remained under veterinary care. Monkeys were
pair-housed in spacious cages enriched with branches and
padded shelter on the floor. Daily diet consisted of commercial
food pellets of New World monkeys (Special Diet Serviced,
Witham, Essex, UK), supplemented with raisins, peanuts,
marshmallows, biscuits, fresh fruit, maggots and gum. Drink-
ing water was provided ad libitum.
According to the Netherlands’ law on animal experimen-
tation, the procedures of this study was reviewed and ap-
proved by the institute’s ethics committee before initiation
of the experiments.
Antigens
Human MOG extracellular domain (rhMOG) was expressed
as an unglycosylated recombinant protein in Escherichia coli
and purified in the BPRC laboratory, as previously described
(Kerlero de Rosbo et al. 1997; Smith et al. 2005). All synthetic
peptides based on the human MOG sequence, which were
used for in vitro assays, were purchased from Cambridge
Research Biochemicals Limited (Cleveland, UK).
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EAE induction and clinical scoring
EAE was induced with 100 μg of rhMOG emulsified in
CFA as previously described (Kap et al. 2010). All animals
were daily monitored for neurological signs using a standard
scoring systems (Kap et al. 2008; Jagessar et al. 2010).
Briefly, 00no clinical signs; 0.50apathy, loss of appetite,
altered walking pattern without ataxia; 10lethargy, anorexia,
loss of tail tonus, tremor; 20ataxia, optic disease; 2.50
paraparesis or monoparesis, sensory loss; 30paraplegia
or hemiplegia; 40quadriplegia; 50spontaneous death due to
EAE. The clinical end-point for each monkey was score 3 and
overt neurological symptoms were observed from score 2.
Experimental design
The study protocol was identical to a prior efficacy evalua-
tion of a fully human anti-CD20 antibody (HuMab7D8) in
the same rhMOG/CFA model(Kap et al. 2010). The human
anti-BLyS antibody (Benlysta; also known as belimumab)
and anti-APRIL antibodies were provided by Human
Genome Sciences, Inc. (Rockville, MD). Binding affini-
ties of the anti-BLyS and anti-APRIL mAbs with recom-
binant human and marmoset BLyS and APRIL were
determined by BIAcore analysis. Anti-BLyS bound with sim-
ilar affinity to human BLyS (Kd 447±30 pM) and marmoset
BLyS (Kd 744±32 pM), whereas binding of the anti-human
APRIL mAb to marmoset APRIL (Kd 19.7±6.6 nM) was
about 8-fold lower than to human APRIL (Kd 2.4±1.4 nM).
All monkeys were randomized to three groups of 6. Anti-
BLyS and anti-APRIL mAbs were administered intrave-
nously at a dose of 10 mg/kg (1 ml/kg) once a week from
day 21 after immunization until the end of the study. The
control group received buffered saline (1 ml/kg) also once
per week from day 21 after immunization.
It is important to point out that the genetic heterogeneity
of the marmoset implies a highly variable response of indi-
vidual animals in the model at the clinical, pathological and
Table 1 Overview of marmoset used in this study and the post-mortem MRI read-outs of white (WM) and grey (GM) matter lesions in one cerebral
hemisphere
Group Animal DOSa Ageb MRI lesions
Volume (mm3) T2 (sec) MTR (%)
WM GM WM GM WM GM
Control M02061 30 102 0 0 – – – –
M05053 57 62 540.7 34 65.9 71.7 29.3 26.5
M07052 40 41 0 0 – – – –
M08071 50 26 0 0 – – – –
M08103 45 25 0 0 – – – –
Mi010311 55 114 1.1 0 64.9 – 31.8 –
Mean±SD 46±10 62±38 270±382 34±n/a 65±0.7 72±n/a 31±2 26±n/a
Anti-BLyS Mi016 102 153 189.5 10.4 64.2 68 32.3 26.6
M03163 93 82 0 0 – – – –
M05025 75 66 330.8 20.0 65.5 70.6 32.4 26.3
M07088 79 45 0 19.6 – 70.1 – 27.6
M08099 56 25 0 0 – – – –
M09017 52 19 398.6 54.7 68.1 75.2 30.7 25.3
Mean±SD 76±20 65±49 306±107 26±20 66±2 71±3 31±1 27±2
Anti-APRIL M0169 64 108 170.7 13.4 68.1 73.6 30.4 24.7
M08029 43 30 186.4 27.9 66.8 76.5 32.0 26.0
M05049 94 62 28.7 1.1 60.7 72.5 35.0 28.8
M07036 109 42 1.8 0 – – 34.1 –
M08092 52 25 0.4 0 – – 32.3 –
M09031 52 18 0 0 – – – –
Mean±SD 69±26 48±33 78±93 14±13 62±5 74±2 33±2 27±2
All animals were males
a Day of sacrifice
b Age in months at the start of the experiment
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immunological level. In agreement with guidelines by
the institute’s animal experimentation committee we
used power calculation to assess the minimal group size
for statistical evaluating the treatment on the disease
course. An inherent problem of the genetic variation in
the model is that underlying immunopathogenic mecha-
nisms are variable and do not develop synchronously. For
this reason robust statistical data for secondary disease
parameters are often not obtained. This problem that is
inherent to preclinical research with higher species has
recently been discussed elsewhere (Bacchetti et al.
2011).
Post-mortem examination
Monkeys selected for necropsy were first deeply sedated by
intramuscular injection of alfaxan (10 mg/kg) (Vétoquinol
S.A., Magny-Vernois, France). After collection of the max-
imum venous blood (PBMC) in EDTA vacutainers, animals
were euthanized by infusion of sodium pentobarbital
(Euthesate®, Aphormo, Duiven, The Netherlands). At nec-
ropsy brain and spinal were removed for (immuno)histolog-
ical examination and magnetic resonance imaging (MRI).
Secondary lymphoid organs were aseptically removed for
preparation of mononuclear cell (MNC) cultures; axillary
(ALN), inguinal (ILN), lumbar (LLN) lymph node and
spleen as previously described (Jagessar et al. 2008; Jagessar
et al. 2010; Kap et al. 2010; Jagessar et al. 2012b). Femur was
collected for isolation of bone marrow (BM) cells. Number of
leukocytes, neutrophils and lymphocytes in blood was mea-
sured on an automated haematology analyzer (Sysmex XT-
2000iV, Norderstedt, Germany).
T cells proliferation
Proliferation was tested on MNC isolated from venous
blood (EDTA) every two weeks or at necropsy from spleen
and secondary lymph nodes (ALN, ILN, LLN) against a
panel of overlapping MOG peptides (10 μg/ml) and rhMOG
(10 μg/ml). Proliferation was expressed as stimulation index
(SI), which is defined as the ratio between [3H]-thymidine
incorporation in the stimulated versus unstimulated cultures
(Jagessar et al. 2008). SI values above 2 were considered
positive.
MNC phenotyping
MNC were phenotyped as previously described (Jagessar
et al. 2010; Jagessar et al. 2012b) and proliferating cells
identified via CFSE vital dye dilution (Kap et al. 2008).
Flow cytometry data were collected on a FACS LSRII
cytometer and analysed with the FACSDiva software 5.0
(BD Biosciences).
Cytokine profiling by ELISA
Supernatants of MNC cultures were collected after 48 h
stimulation with rhMOG or a panel of overlapping MOG
peptides. Supernatants were assayed according to manu-
facturer’s instruction with commercial available ELISA
kits for monkey IFN-γ, monkey TNF-α (U-Cytech,
Utrecht, The Netherlands) and human IL-17A (eBio-
science, San Diego, CA).
Quantitative PCR
Total RNA was extracted from PBMC, spleen and ALN
using RNAeasy minikit (Qiagen, Hilden, Germany).
Subsequently, cDNA was synthesized for qPCR using
primer and probe combination according to the Univer-
sal Probe Library (Roche, Indianapolis, In) as previous-
ly described (Jagessar et al. 2012a). Transcript levels
were normalized against the reference gene Abelson
(ABL).
Autoantibody detection
Immune sera were tested for the presence of IgM and IgG
antibodies binding rhMOG or a panel of overlapping 23-mer
pMOG sequences with ELISA as previously described
(Jagessar et al. 2010).
Statistical analysis
Data are presented as mean±sem. Statistical analysis was
performed using the Mann-Whitney U test. Survival was
evaluated using Log-Rank test. p values≤0.05 were consid-
ered significant.
Results
Induction of B cell depletion by anti-BLyS and anti-APRIL
antibodies
Eighteen unrelated common marmosets were randomized
to 3 groups of 6 animals each (see Table 1). EAE was
induced in all animals by a single immunization with
rhMOG in CFA. Treatment with anti-BLyS and anti-
APRIL was started 21 days after the immunization, but
before clinically evident EAE was observed. Both anti-
bodies were administered as a weekly intravenous dose
of 10 mg/kg (1 ml/kg); the control group received the
same volume of buffered saline.
We tested B cell depletion,by flow cytometric analysis of
CD20 and CD40 expression on MNC, and qPCR analysis of
CD19 mRNA transcripts (Kap et al. 2010). Figure 1a shows
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subsets of circulating marmoset CD20+ cells expressing low
CD40 (±7 %) or high CD40 (± 13 %). Figure 1b depicts the
longitudinal analysis of both subsets after immunization
with rhMOG/CFA, showing that the percentage CD20+
Fig. 1 B cell depletion by anti-BLyS and anti-APRIL antibodies. a.
CD20+ and CD40+ expression by PBMC was analysed by flow cytom-
etry. Based on CD40 expression two populations could be defined,
namely CD20+CD40high (13 %, dark shaded) and CD20+CD40+low
(7 %, light shaded). Depicted data are from monkey M02061 as a
representative example. b. CD20+ (left panel) and CD20+CD40+ (right
panel) expression was measured in PBMC collected at the indicated time
points. The CD20+CD40+ includes the CD20+CD40+high and CD20+
CD40+low population The grey shaded area indicates the period of
treatment, which was started at post sensitization day (psd) 21. Percen-
tages on the y-axes are cell numbers expressed relative to the total
analysed cell number (mean±SEM). CD20+ B cells are reduced by the
anti-BLyS and anti-APRIL treatment compared to untreated monkeys,
but this is not the case for CD20+CD40+ mature B cells. c. MNC were
prepared from blood, spleen, ALN, ILN and BM at necropsy to measure
the presence of CD20+ B cells (left panel) and CD20+CD40+ mature B
cells (right panel). Given percentages on y-axes indicates the fraction of
stained cells from the total measured cells (mean±SEM). In the anti-
BLyS treated group a significant decrease of CD20+ B cells was detected
in all tested organs except BM. Anti-APRIL treatment had only in blood a
significant effect on CD20+ B cells. For the CD20+CD40+ cells no
differences were observed between the control and antibody treated
groups. d. At necropsy also the expression levels of CD19 mRNA tran-
scripts weremeasured in PBMC, spleen and ALN, showing a reduction in
both antibody-treated group, although the differences with anti-APRIL
were only significant for spleen and ALN. Data was normalized to the
household gene ABL (mean±SEM). *p<0.05 Mann Whitney U test,
treated group vs. control group
J Neuroimmune Pharmacol (2012) 7:557–570 561
cells first decreased slightly in control monkeys followed by
a clear increase. The percentage CD20+ cells decreased in
the groups treated with anti-BLyS and anti-APRIL mAb.
Interestingly CD20+ cells expressing high CD40 were not
depleted by the treatment.
To assess whether the depletion of B cells was sys-
temic and long lasting we analysed expression of CD20
and CD40 on MNC isolated from blood, spleen, axillary
and inguinal lymph nodes and bone marrow collected at
necropsy (Fig. 1c). In the anti-BLyS treatment group we
observed significant reduction of CD20+ cells in blood
and lymphoid organs, but not in the BM. In the anti-
APRIL group a significant effect on CD20+ B cells
depletion was only observed in blood, whereas the per-
centage CD20+ cells seemed increased in the spleen.
Again, the two antibodies had no detectable effect on
the percentage of CD20+CD40+ cells.
The flow cytometry data for the anti-BLyS treated group
were confirmed by the analysis of mRNA transcript levels
for CD19 (Fig. 1d). However, we observed an unexplained
discrepancy between the increased CD20 staining and re-
duced CD19 mRNA level in the spleen of anti-APRIL
treated monkeys
Taken together these data show that the anti-BLyS anti-
body consistently decreases B cell number in blood, spleen
and lymph nodes, while a variable effect of the anti-APRIL
antibody was observed in the monkeys.
Plasma antibody levels as a surrogate marker of systemic B
cell reduction
We tested plasma antibody levels against the immunizing
rhMOG protein and two B cell epitope containing peptides,
i.e. MOG24-46 and MOG54-76, as an independent bio-
marker of systemic B cell depletion. Similar to previous
studies, IgM serum antibodies against rhMOG in control
monkeys peak during a short time interval after the immu-
nization. Serum IgG antibodies come up somewhat later and
remain high. Essentially the same patterns are observed for
Fig. 2 Anti-BLyS treatment
reduced antibody production.
Plasma samples collected at two
weeks interval and necropsy
were tested with ELISA for the
presence of IgM (a) and IgG (b)
antibodies against the B-cell
epitopes MOG24-46 and
MOG54-76, and against intact
rhMOG. In the anti-BLyS trea-
ted group, reduction of IgM and
IgG levels were observed dur-
ing the entire study, but in the
anti-APRIL treated groups IgM
as well as IgG remained high.
Mann Whitney U test has been
performed but no significantly
differences were observed
bFig. 3 Delay of EAE course by anti-BLyS and anti-APRIL treatment.
a. Clinical scores are depicted of controls (left panel) and the two
antibody treated groups, with anti-BlyS (middle panel) or anti-APRIL
(right panel). The solid lines represent clinical scores (left y-axes) and
the dotted line body weight loss relative to the immunization day,
defined as post sensitization day (psd) 0. Grey shaded boxes indicate
the treatment period. All animals in the experiment developed clinical-
ly evident EAE (clinical score 2.0) and most of them were sacrificed
with an EAE score of 3.0. However, monkey Mi016, M0169 and
M05049 had to be sacrificed at an earlier time point due to the serious
body weight loss. b. Survival curves depict the disease free survival
time (time interval to development of EAE score 2.0; left panel) and
overall survival (time interval to clinical end point; right panel). Dis-
ease free survival times were significantly prolonged in the anti-BLyS
and anti-APRIL treated monkeys. The total survival was significantly
prolonged by the anti-BLyS treatment, but the delay in anti-APRIL
treated monkeys was not significant (p00,0646). *p<0.05; **p<0.001
Log-rank test, treated group vs. control group
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IgM (Fig. 2a) and IgG (Fig. 2b) antibodies against the two
peptides. However, the antibody profiles differed clearly
between the anti-BLyS and anti-APRIL treated groups. In
general IgM antibody levels in the monkeys treated with
anti-BLyS mAb remained markedly lower than in the group
treated with anti-APRIL mAb. For IgG antibody levels this
effect was less clear. The plasma level of anti-rhMOG IgG
antibodies was clearly suppressed in the anti-BLyS treated
group compared to the control group, whereas an inconsistent
variable effect was observed for the anti-APRIL treated group.
Delayed EAE onset by anti-BLyS and anti-APRIL treatment
All animals in all the three groups developed clinically evident
EAE and were sacrificed with a maximum score of 3, which
was taken as the predefined ethical end-point. The graphs in
Fig. 3a depict the clinical score and body weight loss of
individual monkeys relative to the day of EAE induction
(psd 0). Some monkeys (Mi010311, Mi016, M03163 and
M05049) went into remission after a short period of visual
problems reminiscent of optic neuritis. Two animals in the anti-
APRIL group (M0169 andM05049) and one in the anti-BLyS
group (Mi016) were sacrificed with an EAE score of 2. The
reason for sacrifice, before the ethical end-point was reached,
was the high bodyweight loss and low physical activity.
Comparison of the time interval to the onset of clin-
ically evident EAE (score 2.0) of the anti-BLyS and anti-
APRIL groups with the control group showed a signifi-
cantly delayed disease onset (disease-free survival curves
in Fig. 3b). The subsequent disease progression to the
ethical end-point (score 3.0) was also delayed in both
groups. However, the delay was statistically significant
for the group treated with anti-BLyS mAb, but not for
the anti-APRIL treated group (p00.0646).
Effect of the anti-BLyS and anti-APRIL mAbs on CNS
pathology
Histological analysis of the spinal cord shows reduced in-
flammation in the anti-BLyS and anti-APRIL group com-
pared to the controls. However, the differences in individual
monkeys were too variable to reach statistical significance
(Fig. 4a). The histology data also show a higher mean
percentage demyelination of the brain in the anti-BLyS
treated group, but also these differences were not statistical-
ly significant. In contrast, the anti-BLyS treated group dis-
played a significantly lower severity of spinal cord
demyelination, while this was not observed for in the group
treated with anti-APRIL mAb (Fig. 4b). Quantification of
demyelination of the optic nerve suggested also a protective
effect of the anti-BLyS and anti-APRIL mAbs. In the mAb
treated groups 2/6 monkeys showed 100 % demyelination
of the optic nerve while in the control group there were 4
control monkeys with 100 % demyelination.
In conclusion, the histology data show a remarkable
opposite effect of the anti-BLyS treatment on brain and
spinal cord demyelination. This was not observed with the
anti-APRIL mAb.
Effect of the mAb on ex vivo T cell proliferation
As a read-out for T cell proliferation we determined incor-
poration of [3H]-thymidine (T-cell proliferation assay:
TCPA) and CFSE vital dye dilution (Fig. 5).
Fig. 4 Reduced spinal cord
demyelination in anti-BLyS
treated monkeys. Formalin-
fixed tissue samples were
stained to analyse the intensity
of inflammation and demyelin-
ation. For each animal 8 slices
were examined, which equals
6 cm2 in total. a. The number of
infiltrated cells per mm2 is giv-
en for the spinal cord. The
amount of demyelination is
given for the spinal cord (b),
optic nerve (c) and brain white
matter (d). A significant treat-
ment effect was only observed
for the spinal cord of anti-BLyS
treated animals. *p<0.05
Mann-Whitney U test, antibody
treated group vs. control group
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TCPA Figure 5a shows the longitudinal proliferation of
PBMC against the immunizing rhMOG protein, the pep-
tides MOG14-36 and MOG24-46, which contain the
MOG24-36 epitope of early acting Caja-DRB*W1201
restricted CD4+ Th1 cells (Brok et al. 2000) and
MOG34-56, which contains the MOG40-48 epitope of
late acting Caja-E restricted CD4+CD8+ cytotoxic T
lymphocyte (CTL) (Kap et al. 2008; Jagessar et al.
2012b). During the initial 40 days after immunization
the differences between the three groups were relatively
small. However, at psd 42 we observed a increase of
PBMC proliferation in the control and anti-BLyS-treated
groups, while proliferation in the anti-APRIL treated
group remained low. At 14 days later all control
monkeys had been taken out of the experiment with
clinically evident EAE. From psd 58 onwards PBMC
proliferation in the anti-BLyS group was usually higher
than in the monkeys treated with anti-APRIL mAb.
We also determined the proliferative response of MNC
from blood and lymphoid organs at the height of the disease
(Fig. 5b). The figure shows that the proliferation of MNC
from spleen and LLN against the tested MOG peptides is
consistently higher than that of the control and anti-APRIL-
treated monkeys. No significant difference was found for
Fig. 5 Modulation of T cell proliferation in anti-BlyS and anti-APRIL
treatedmonkeys. a. PBMCwere isolated at the indicated time points (psd;
post sensitization day) and assayed for the response to stimulation with
rhMOG or 23-mer synthetic peptides containing previously identified
dominant MOG T cell epitopes, i.e. MOG14-36, MOG24-46 and
MOG34-56. The read-out was incorporation of [3H]-thymidine during
the final 18 h of 3 days culture. Data on the left panel show the stimulation
index (SI). Grey shaded boxes indicate the period of treatment. T cell
proliferation increased after immunization, and was significantly en-
hanced during the anti-BLyS treatment, but was reduced during anti-
APRIL treatment. b. At necropsy the incorporation of [3H]-thymidine
was measured as a read-out for proliferation in PBMC, spleen, ALN, ILN
and LLN against the same MOG antigens as described under (A). c.
Proliferated Tcells in blood and lymphoid organs were phenotyped using
the CFSE diluting assay. Data are shown ofMNC derived from spleen, as
a representative example. Stimulation with MOG34-56 and rhMOG are
depicted. The y-axes indicates the percentage proliferated cells; CD4+,
CD8+ and double positive for CD4 and CD8 were first gated within the
CD3+ proliferated population, next for CD4+CD56+, CD8+CD56+ and
CD4+CD8+CD56+, respectively. Data are presented as mean±SEM. *p
<0.05 Mann Whitney U test, antibody treated group vs. control group
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the MNC proliferation against the immunizing rhMOG pro-
tein between the anti-BLyS treated and control monkeys.
CFSE dilution Flow cytometric analysis of CFSE labelled cells
for dye dilution in combination with mAb staining was used to
assess whether proliferation maps to a certain subset of T cells.
We have focused on the response of spleen MNC against
MOG34-56 as these contain the T cells that are the most likely
culprit for the induction of neurological deficits (Kap et al. 2008)
mainly localize in the spleen (Jagessar et al. 2010).
Freshly isolated spleen cells were stained with CFSE and
subsequently cultured for 7 days without antigen and with
MOG34-56 or rhMOG. Cells harvested from the cultures
were incubated with selectedmonoclonal antibodies and bind-
ing was analysed by flow cytometry. The results are given in
Fig. 5c. A first remarkable observation was that unstimulated
CD3+ spleen MNC from monkeys treated with anti-BLyS
mAb contain a significantly higher number of cells with CFSE
dilution than CD3+ spleen MNC from control or anti-APRIL
treated monkeys. This higher background proliferation in
these animals localizes in the CD4+CD56+ subset. Seven
days culture of the spleen cells with MOG34-56 did not
detectably enhance proliferation of CD3+ cells and the
CD3+CD4+(CD56+) subsets in all three groups, but prolifer-
ation of CD3+CD8+ and CD3+CD8+CD56+ cells was mark-
edly, albeit non-significantly, enhanced in the anti-BLyS treated
group. By contrast, 7 days stimulation of spleen cells with
rhMOG induced significantly enhanced proliferation of
CD3+ spleen cells, which localized to the CD3+CD8+,
CD3+CD4+CD8+ and CD3+CD4+CD8+CD56+ subsets.
Collectively, these data show that the treatment with anti-
APRIL had a less outspoken modulatory effect on the ana-
lysed cellular responses than the anti-BLyS treatment. This
is in accordance with the postulate that the primary focus of
APRIL activity is in the humoral arm of the immune system,
whereas BLyS is involved in cellular as well as humoral
immune mechanisms (Moisini and Davidson 2009).
Altered cytokine levels with anti-BLyS and anti-APRIL
The immunization of marmosets with rhMOG/CFA activates
both Th1 and Th17 cells, which are both pathogenically
relevant in this model, although they seem to operate in
different pathways (Kap et al. 2010). We used ELISA to
Fig. 6 Altered cytokine expression with anti-BLyS and anti-APRIL. a.
At necropsy MNC were collected from blood and lymphoid organs and
cultured for 48 h with a panel of MOG peptides and rhMOG. Levels of
IL-17A (left panel), TNF-α (middle panel) and IFN-γ (right panel)
were measured in culture supernatants with ELISA (mean±SEM).
Data is only shown of rhMOG stimulated MNC, since no high levels
of cytokines were measured in the MOG peptide stimulated cells. b.
Cytokine mrRNA transcripts of IL-17A, TNF-α, IFN-γ, IL-7 and IL-
10 were measured in PBMC, spleen and ALN. Data was normalized to
the household gene ABL (mean±SEM). Mann Whitney U test was
performed as statistical calculation, but no significant differences were
observed
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determine the ex vivo production of IL-17A, TNF-α and IFN-γ
proteins by MNC from blood, spleen and ALN after stimula-
tion with the immunizing rhMOG antigen. Moreover, we de-
termined the levels of mRNA transcripts for several cytokines
to assess presence of functionalMNC subsets: Th1 (TNF-α and
IFN-γ), Th17 (IL-17A), Treg (IL-10) and IL-7 (B cells).
The profiles of cytokines secreted in the rhMOG-
stimulated cultures are displayed in Fig. 6a. This graph shows
a trend towards reduced IL-17A production in all three ana-
lysed compartments of the anti-BLyS-treated animals, com-
pared to both other groups, whereas the levels of TNF-α and
IFN-γwere increased. The rhMOG stimulation of MNC from
the control and anti-APRIL treated monkeys induced essen-
tially similar secretion levels of IL-17A, TNF-α and IFN-γ.
However, due to the inter-individual variation in the outbred
model, none of these effects reached statistical significance.
The analysis with cytokine specific qPCR of mRNA
directly extracted from blood, spleen and ALN MNC shows
inconsistent effects of the anti-BLyS and anti-APRIL treat-
ment (Fig. 6b). Both antibodies induced reduced IL-17A
and IFN-γ transcript levels in spleen, whereas levels in
ALN are increased in monkeys treated with anti-BLyS
mAb but decreased by anti-APRIL treatment. Remarkably,
in the anti-BLyS group increased transcript levels for TNF-
α were detected in spleen, whereas these were unchanged in
ALN. In the anti-APRIL group TNF-α transcripts were
reduced in ALN and unaltered in spleen. Interestingly, the
transcript levels for IL-10 in spleen and ALN were enhanced
in anti-APRIL treated monkeys, whereas the levels were
unaltered in spleen and ALN from the anti-BLyS group.
Finally, we observed marginally reduced IL-7 mRNA levels
in spleen from the anti-BLyS and anti-APRIL treated
monkeys, where these cytokines were unaltered in ALN.
In conclusion, both antibodies exerted a modulatory ef-
fect on the cytokine profiles of rhMOG-reactive T cells,
although the direction of the effect can be opposite for
several cytokines.
Discussion
The rhMOG/CFA induced EAE model in marmosets has
presented itself as a useful preclinical model for translational
research intoMS pathogenesis (’t Hart et al. 2011). On the one
hand the model shares well-documented features with the
equivalent EAE models in mice and rats. On the other hand
the model shares clinical and pathological features with MS,
in particular the progressive course and the prominent in-
volvement of grey matter demyelination (’t Hart et al. 2011).
The disease course of the model is not only variable,
reflecting the genetic heterogeneity of the marmoset as an
outbred species, but also highly complex, affecting the white
and grey matter of the brain and spinal cord. As discussed
elsewhere (’t Hart et al. 2011), the induction of inflammation
and demyelination and the ensuing neurological deficits
involves at least two pathways. The “canonical” pathway I
seems to be primarily active in the initiation phase of the
disease and involves the concerted action of MHC class II-
restricted Th1 cells and autoantibodies. In vivo activation
(Brok et al. 2000)or adoptive transfer (Villoslada et al. 2001)
of only the Th1 cells induces small inflammatory lesions
without demyelination. Demyelination is effected when
monkeys are immunized with B cell epitope containing
rhMOG protein or by transfer of monoclonal antibody against
MOG protein (Genain et al. 1995). It should be noted that
pathway I is not strictly dependent of MOG, as it is also
inducible with MOG-deficient myelin, whereas for the acti-
vation of pathway II, MOG seems indispensable (Jagessar et
al. 2008). The “non-canonical” pathway II becomes likely
engaged later in the pathogenic process and involves MHC
class I-restricted effector memory natural killer-like cytotoxic
Tcells (NK-CTL) interacting with Th17 cells (Kap et al. 2008;
Jagessar et al. 2010; Jagessar et al. 2012b). The MHC-class II
(Caja-DRB*W1201) and MHC class I (Caja-E) restriction
elements, respectively operating in pathways I (Brok et al.
2000) and II (Jagessar et al. 2012b) are both monomorphic in
the common marmoset, explaining why the two pathways can
be operational in all animals.
B cells have a pathogenic contribution to both pathways.
The main role of B cells in the canonical pathway I is the
production of autoantibodies against myelin, which elicit cel-
lular and/or complement dependent cytotoxicity reactions.
The primary role in the non-canonical pathway II, which is
independent of autoantibodies, is antigen presentation to the
NK-CTL that induces demyelination of grey and white matter
without detectable involvement of autoantibodies. The latter
role of B cells was shown in two independent experiments.
One set of experiments demonstrated that depletion of B cells
with the anti-CD20 antibody HuMab7D8 from marmosets at
21 days after the immunization with rhMOG/CFA abrogates
the development of EAE symptoms (Kap et al. 2010) as well
as of EAE pathology in the grey and white matter of the brain
and spinal cord (Kap et al. 2011). This highly robust effect
was associated with impaired activation of the cellular auto-
immune mechanisms that mediate disease progression. A
second set of experiments was performed in the novel
MOG34-56/IFA EAE model in which white and grey matter
demyelination is induced by peptide-specific NK-CTL with-
out a detectable influence of autoantibodies (Jagessar et al.
2010; Jagessar et al. 2012b). In the same MOG34-56/IFA
EAE model it was observed that depletion of CD20+ B cells
from 21 days after the immunization abrogates the develop-
ment of EAE symptoms and pathology (submitted for
publication).
We report here the effect on the rhMOG/CFA EAE model
of two monoclonal antibodies against essential factors for B
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cell survival and differentiation. BLyS and APRIL have
partially overlapping roles in B cell survival and differenti-
ation involving at least 3 receptors, i.e. BCMA, TACI and
BR3, which recognize homo-trimeric forms of BLyS and
APRIL (Miller et al. 2006). BLyS binds to all three recep-
tors, but with highest affinity for BR3. APRIL does not bind
BR3 and has about 100-fold higher affinity for BCMA than
BLyS. TACI binds both factors with comparable affinity.
The results of the current study show that anti-BLyS and
anti-APRIL administration to rhMOG/CFA immunized mar-
mosets induced depletion of CD20+ B cells from blood at a
similar rate and depth. Similar to observations in cynomol-
gus monkeys the depletion with anti-BLyS mAb was less
fast or profound than with anti-CD20 mAb (Halpern et al.
2006). In the monkeys treated with anti-BLyS, but not in
those treated with anti-APRIL we observed reduction of
CD20+ B cells in spleen and lymph nodes. With qPCR
analysis it was also shown that CD19 transcript levels were
reduced in spleen and ALN of anti-BLyS as well as anti-
APRIL treated monkeys. It is difficult to explain these
discrepancies although it should be noted that CD20 is an
exclusive marker of the B cell lineage, whereas CD19 is also
expressed by the follicular dendritic cells that populate
lymphoid organs. Interestingly, we observed no depletion
by anti-BLyS or anti-APRIL mAb of the CD20+CD40+
subset. This subset is actively engaged in the EAE patho-
genesis as illustrated by the finding that administration of
antagonist anti-CD40 mAb suppressed EAE development in
the rhMOG/CFA model (Boon et al. 2001). However, dis-
ease activity within the CNS was only partly suppressed.
This is a remarkable difference with the robust clinical (Kap
et al. 2010) and pathological (Kap et al. 2011) effect of anti-
CD20 mAb treatment in the rhMOG/CFA model, in which
complete depletion of the CD20+CD40- and CD20+CD40
+ subsets was observed. Collectively, these data show that
for an optimal clinical effect of B cell targeting antibodies in
the rhMOG/CFA model probably both subsets of B cells
have to be depleted.
The separate antibody-mediated inhibition of BLyS and
APRIL exerted comparable clinical effects in the EAE mod-
el, although several differences at the immunological and
pathological level were observed. Neutralization of BLyS or
APRIL caused a significantly delayed onset of overt clinical
EAE (EAE score 2.0, ataxia). However, the effect on the
time to the study end-point (EAE score 3.0, hemi-/paraplegia)
was statistically significant only for the group treated with
anti-BLyS antibody. Moreover, in the monkeys treated with
anti-BLyS, but not in those treated with anti-APRIL, we
observed significantly reduced demyelination of spinal cord.
These discrepant effect may be explained by the fact that the
anti-BLyS antibody targets not only processes in the periph-
ery, i.e. B cell survival, but also in the CNS, i.e. neuronal
outgrowth. BLyS is produced within the CNS by reactive
astrocytes and exerts via NgR1 similar effects on neurons as
the natural ligand Nogo66 (Zhang et al. 2009). To our knowl-
edge, such non-immunological effects in the EAEmodel have
not been reported for APRIL.
The two mAbs were found to modulate, albeit in a
different manner, cellular autoimmune reactions involved
in the EAE pathogenesis. This was observed in regular
proliferation assays using MNC isolated from different im-
mune compartments; response patterns of T cell subsets
assessed by CFSE vital dye dilution and the cytokine pro-
files. We observed in the anti-BLyS-treated group enhanced
proliferation of MNC from blood and lymphoid organs
against MOG peptides 14–36 and 24–46, which both con-
tain the epitope MOG24-36 that is presented by a ubiqui-
tously expressed monomorphic Caja-DRB*W1201 allele to
Th1 cells (Brok et al. 2000; Doxiadis et al. 2006). The
higher production of TNF-α and IFN-γ by the rhMOG-
stimulated splenocytes supports this conclusion. We observed
lower production of IL-17A than in the other two groups i.e.
anti-APRIL and the controls. Phenotyping of proliferating
cells via CFSE vital dye dilution and monoclonal antibody
staining shows that CD3+ T cells from anti-BLyS treated
monkeys displayed higher proliferative activity than those
from the other two groups, which are localized mostly within
the CD4+CD56+ subset. However, the rhMOG andMOG34-
56-stimulated proliferation are localized mainly in the CD8+,
CD4+CD8+, CD8+CD56+ subsets. Importantly, the reactiv-
ity of the CD4+CD8+CD56+ subset to antigenic stimulation,
which is the main source of the autoreactive T cells cytotoxic
activity in the marmoset EAE model (Jagessar et al. 2010;
Jagessar et al. 2012b), is not increased by the treatment.
In the monkeys treated with the anti-APRIL mAb we did
not observe marked differences with the control monkeys at
the level of proliferation by MNC from blood, spleen or
lymph nodes, neither in the TCPA test nor with CFSE vital
dye dilution. However, the cytokine analyses showed the
lowest expression of pro-inflammatory cytokines IL-17A,
IFN-γ and TNF-α mRNA transcripts concomitant increased
expression of anti-inflammatory IL-10 mRNA in this group.
In conclusion, the treatment with anti-BLyS and anti-
APRIL antibody, which was started at a relatively late stage
(day 21 post immunization), results in a significant delay of
EAE onset and progression. Due to the heterogeneity between
individual monkeys, which is inherent to this outbred model,
differences between investigated variables in the three groups
often did not reach statistical significance. This implies that
they should be interpreted with caution as only trends can be
indicated. The clinical effect of the therapeutic antibodies
seems to be based on different mechanisms. The anti-BLyS
treated group displays reduced antibody levels against
rhMOG and MOG peptides, together with reduced Th17 and
increased Th1 activation. We hypothesize that treatment with
the anti-BLyS antibody may impair both the canonical and the
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non-canonical pathogenic pathway. Besides this immuno-
modulatory effect, the depletion of BLyS could also have
consequences inside the CNS, such as removal of axonal
outgrowth inhibition. For the anti-APRIL antibody such cen-
tral effects are not known, which may explain why the disease
progression after initiation (score 2.0 to 3.0) is not significant-
ly affected. However, the antibody has modulatory effects on
the autoimmune reaction, most notably a reduction of Th1 and
Th17 signature cytokine transcripts and an increase of IL-10
mRNA. This may suggest that the inhibitory activity of the
anti-APRIL mAb mainly affects pathway I (B cells/auto-
antibodies), and is based on skewing from a pro- to anti-
inflammatory T cell profile. Further research should demon-
strate whether this is indeed the case.
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